AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27287832 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab vs Methotrexate
Number of subjects: 317
Study 27287832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate vs Tocilizumab
Number of subjects: 317
Study 27287832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 317
Study 27287832 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 317
Study 24331381 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous yellow fever virus (YFV) vaccination
Number of subjects: 0
Study 24331381 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous yellow fever virus (YFV) vaccination
Number of subjects: 0
Study 22529163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl therapy
Number of subjects: 3883
Study 22529163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study 19243009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiosurgery (20 or 24Gy targeting the amygdala, hippocampus, and parahippocampal gyrus)
Number of subjects: 30
Study 19243009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiosurgery (20 or 24Gy targeting the amygdala, hippocampus, and parahippocampal gyrus)
Number of subjects: 30
Study 19243009 — intervention group
Group type: COMPARATOR
Intervention: Both high-dose and low-dose radiosurgery
Number of subjects: 30
Study 19243009 — intervention group
Group type: COMPARATOR
Intervention: High-dose and low-dose radiosurgery
Number of subjects: 30
Study 17544497 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of platinum-based chemotherapy followed by surgery (CT-S)
Number of subjects: 519
Study 17544497 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 519
Study 17544497 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (CT-S)
Number of subjects: 519
Study 17544497 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (combined systematic review including present result)
Number of subjects: 519
Study 15099420 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance interpersonal psychotherapy for 2 years
Number of subjects: 125
Study 11448378 — intervention group
Group type: COMPARATOR
Intervention: QI-therapy
Number of subjects: 1299
Study 11448378 — intervention group
Group type: COMPARATOR
Intervention: QI-meds
Number of subjects: 1299
Study 11448378 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 1299
Study 9710334 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion gain fittings
Number of subjects: 40
Study 9710334 — intervention group
Group type: COMPARATOR
Intervention: Median ear corrected coupler fittings
Number of subjects: 40
Study 7697844 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 1012
Study 2540789 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (M series: 131 patients)
Number of subjects: 497
Study 2540789 — intervention group
Group type: COMPARATOR
Intervention: No maintenance chemotherapy (NoM series: 134 patients)
Number of subjects: 497
Study 2540789 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complete response to initial chemotherapy (99 patients)
Number of subjects: 497
Study 2540789 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 497
Study 2540789 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chemotherapy
Number of subjects: 497
Study 2540789 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival at 1 year
Number of subjects: 497
Study 2540789 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival at 2 years
Number of subjects: 497
Study 2540789 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival at 3 years
Number of subjects: 497
Study 836131 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care preparation
Number of subjects: 572
Study 836131 — intervention group
Group type: COMPARATOR
Intervention: Continued hospitalization
Number of subjects: 572
Study 29994983 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 17-24 years
Number of subjects: 136
Study 29994983 — intervention group
Group type: COMPARATOR
Intervention: Participants aged 11-16 years
Number of subjects: 136
Study 29994983 — intervention group
Group type: COMPARATOR
Intervention: Self-report and SD of tacrolimus trough levels
Number of subjects: 136
Study 28375507 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Tdap 3-4 weeks before PCV13 and MCV4)
Number of subjects: 166
Study 28375507 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (All three vaccines concurrently)
Number of subjects: 166
Study 28375507 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (PCV13 and MCV4 3-4 weeks before Tdap)
Number of subjects: 166
Study 28375507 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 166
Study 25234823 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cognitive-behavioral intervention
Number of subjects: 104
Study 25234823 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 104
Study 25234823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (post-intervention)
Number of subjects: 104
Study 25234823 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (2-year follow-up)
Number of subjects: 104
Study 22158530 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred side of approach
Number of subjects: 83
Study 22158530 — intervention group
Group type: COMPARATOR
Intervention: Non-preferred side of approach
Number of subjects: 83
Study 21575983 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-pegylated liposomal doxorubicin (CD)
Number of subjects: 976
Study 21575983 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (CP)
Number of subjects: 976
Study 19566763 — intervention group
Group type: EXPERIMENTAL
Intervention: Perospirone
Number of subjects: 66
Study 19566763 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 66
Study 17007024 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN‐alpha2a 180 mg subcutaneously once weekly for a year + Ribavirin 1200 mg
Number of subjects: 73
Study 17007024 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha‐2a 3 MU 3 times weekly + Ribavirin 1200 mg
Number of subjects: 73
Study 15017671 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 180
Study 15017671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 15017671 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (300 or 600 mg daily)
Number of subjects: 180
Study 15017671 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 180
Study 11200367 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 11
Study 9292183 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal steroid (budesonide)
Number of subjects: 30
Study 9292183 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 30
Study 7944323 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) products
Number of subjects: 0
Study 7944323 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor product
Number of subjects: 0
Study 7944323 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachlorometaxylenol products
Number of subjects: 0
Study 7944323 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol product
Number of subjects: 0
Study 3336257 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 6
Study 3336257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31249023 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health tool Smart Client (1 welcome call, 13 program calls, 3 quiz calls)
Number of subjects: 565
Study 31249023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 565
Study 28256104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/day for 3 weeks)
Number of subjects: 16
Study 28256104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25438964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain 101 intervention
Number of subjects: 25
Study 25438964 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 22511592 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH+GPI (initial UFH bolus: 60 IU kg(‐1), target ACT: 200‐250 sec)
Number of subjects: 1624
Study 22092941 — intervention group
Group type: EXPERIMENTAL
Intervention: Light scoring using a scalpel
Number of subjects: 101
Study 22092941 — intervention group
Group type: COMPARATOR
Intervention: Marking using a gentian violet marker
Number of subjects: 101
Study 19935373 — intervention group
Group type: COMPARATOR
Intervention: Standard exposure everolimus (C0 3‐8 ng/mL) with low‐concentration cyclosporine A (C2 maintenance levels 350‐500 ng/mL)
Number of subjects: 285
Study 19935373 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exposure everolimus (C0 8‐12 ng/mL) with very low‐concentration cyclosporine A (C2 maintenance levels 150‐300 ng/mL)
Number of subjects: 285
Study 16796694 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg orally twice daily)
Number of subjects: 20
Study 15273706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cyclophosphamide (2 g/m(2)) plus lenograstim at 5 micrograms/kg (Cyclo-G-CSF group)
Number of subjects: 79
Study 15273706 — intervention group
Group type: COMPARATOR
Intervention: Lenograstim alone at 10 micrograms/kg (G-CSF group)
Number of subjects: 79
Study 15273706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cyclophosphamide plus lenograstim (Cyclo-G-CSF group)
Number of subjects: 79
Study 15273706 — intervention group
Group type: COMPARATOR
Intervention: Lenograstim alone (G-CSF group)
Number of subjects: 79
Study 15273706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 10860226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tidal-volume ventilation (6 mL/kg)
Number of subjects: 0
Study 10860226 — intervention group
Group type: COMPARATOR
Intervention: Traditional-tidal-volume ventilation (12 mL/kg)
Number of subjects: 0
Study 9054848 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal medical therapy
Number of subjects: 256
Study 8346750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron prosthetic ligament reconstruction
Number of subjects: 84
Study 2871049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 5 mg
Number of subjects: 206
Study 2871049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 10 mg
Number of subjects: 206
Study 2871049 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 206
Study 2871049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 2.5 mg
Number of subjects: 206
Study 2871049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 31494070 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the dlPFC
Number of subjects: 0
Study 31494070 — intervention group
Group type: EXPERIMENTAL
Intervention: APTD (acute phenylalanine/tyrosine depletion)
Number of subjects: 0
Study 31494070 — intervention group
Group type: COMPARATOR
Intervention: Combination of APTD and anodal tDCS
Number of subjects: 0
Study 29778750 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous crystalloid cardioplegia via vein grafts plus intermittent blood cardioplegia through aortic root (group 1)
Number of subjects: 223
Study 29778750 — intervention group
Group type: COMPARATOR
Intervention: Antegrade blood cardioplegia alone (group 2, control)
Number of subjects: 223
Study 27513162 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP)
Number of subjects: 10
Study 27513162 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone (AB)
Number of subjects: 10
Study 24929926 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Cognitive-Behavioral Treatment (CBT)
Number of subjects: 41
Study 23452265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic hyperpnoea
Number of subjects: 44
Study 23452265 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 21046360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention (diet, exercise, and diet plus exercise)
Number of subjects: 577
Study 21046360 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577
Study 21046360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention
Number of subjects: 577
Study 18955835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (154 mEq/l infusion)
Number of subjects: 145
Study 18955835 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (0.9% solution)
Number of subjects: 145
Study 16551862 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) at 1,200 mg m(‐2)
Number of subjects: 15
Study 16551862 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA)
Number of subjects: 15
Study 12812667 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation
Number of subjects: 1435
Study 12812667 — intervention group
Group type: COMPARATOR
Intervention: Traditional ventilation
Number of subjects: 1435
Study 12812667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of all studies
Number of subjects: 1435
Study 10839291 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment in every arm
Number of subjects: 204
Study 10839291 — intervention group
Group type: COMPARATOR
Intervention: No treatment arm
Number of subjects: 204
Study 10839291 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participation in RCTs
Number of subjects: 204
Study 10839291 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for participating
Number of subjects: 204
Study 10839291 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for declining participation
Number of subjects: 204
Study 8706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm 25
Number of subjects: 196
Study 8706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm 50
Number of subjects: 196
Study 8706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Estraderm 25 and 50
Number of subjects: 196
Study 8706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm 25 (age > 67 years)
Number of subjects: 196
Study 8706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm 50 (age < 67 years)
Number of subjects: 196
Study 8706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm 25 and 50 (overall)
Number of subjects: 196
Study 1879994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapiprazole
Number of subjects: 40
Study 1879994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40
Study 1879994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6120703 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam 0.03 mg/kg
Number of subjects: 30
Study 6120703 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.15 mg/kg
Number of subjects: 30
Study 31821592 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT guided self-help (DBT-GSH)
Number of subjects: 71
Study 31821592 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT unguided self-help (DBT-USH)
Number of subjects: 71
Study 31821592 — intervention group
Group type: COMPARATOR
Intervention: Unguided self-help control (USH)
Number of subjects: 71
Study 31099927 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate
Number of subjects: 0
Study 31099927 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 28063503 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.25 g/kg)
Number of subjects: 13
Study 28063503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 25891654 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of placental extract gel (group S)
Number of subjects: 10
Study 25891654 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 10
Study 23810688 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi particle (9.6 g 3 times per day)
Number of subjects: 190
Study 23810688 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (1 mg/kg/d tapering to 0.17 mg/kg/d) and cyclophosphamide (total dose of 9-12 g/m²)
Number of subjects: 190
Study 21616970 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention deficit/hyperactivity disorder (ADHD)
Number of subjects: 92
Study 21616970 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 92
Study 19291931 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 47
Study 19291931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate
Number of subjects: 47
Study 19291931 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus cyclical etidronate
Number of subjects: 47
Study 19291931 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 47
Study 17251532 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine-artery embolization
Number of subjects: 157
Study 17251532 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 157
Study 15596580 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% unoprostone isopropyl
Number of subjects: 33
Study 15596580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11318054 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to nonspatial stimulus attribute of color
Number of subjects: 0
Study 11318054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspatial responses of varying force
Number of subjects: 0
Study 11318054 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated response effects
Number of subjects: 0
Study 9129792 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusions for neonatal hyperbilirubinemia
Number of subjects: 11
Study 9129792 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma bilirubin concentrations
Number of subjects: 11
Study 8198981 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin 2 (rIL-2) therapy
Number of subjects: 0
Study 2885357 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 300 mg bid for 3 days
Number of subjects: 12
Study 2885357 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg bid for 3 days
Number of subjects: 12
Study 2885357 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine 8 mg three times a day for 3 days
Number of subjects: 12
Study 2885357 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study 29248859 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 517
Study 29248859 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 517
Study 29248859 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban and Warfarin
Number of subjects: 517
Study 28494895 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin infusion at a dose of 2‐5μg/kg/min
Number of subjects: 60
Study 28494895 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol infusion at a dose of 0.5‐2mg/min
Number of subjects: 60
Study 25604764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecosystem management intervention involving collection and elimination of small water holding containers and alteration or covering of large water tanks to prevent mosquito oviposition.
Number of subjects: 20
Study 25604764 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; no direct comparison group mentioned in the abstract.
Number of subjects: 20
Study 24157162 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training (4 hours)
Number of subjects: 30
Study 21129239 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ATP per day for 28 days
Number of subjects: 32
Study 21129239 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 mg ATP per day for 28 days
Number of subjects: 32
Study 21129239 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 mg ATP per day for 28 days
Number of subjects: 32
Study 21129239 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 mg ATP on days 0 and 28
Number of subjects: 32
Study 21129239 — intervention group
Group type: COMPARATOR
Intervention: 0 mg ATP per day for 28 days (control)
Number of subjects: 32
Study 18850558 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% and timolol 0.5% (fixed combination)
Number of subjects: 0
Study 18850558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% and timolol 0.5% (fixed combination)
Number of subjects: 0
Study 18850558 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2% (adjunctive therapy)
Number of subjects: 0
Study 18850558 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% (adjunctive therapy)
Number of subjects: 0
Study 18850558 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol (fixed combination)
Number of subjects: 0
Study 16542051 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinylestradiol 20mug/drospirenone 3mg
Number of subjects: 445
Study 16542051 — intervention group
Group type: COMPARATOR
Intervention: ethinylestradiol 20mug/desogestrel 150mug
Number of subjects: 445
Study 12816885 — intervention group
Group type: EXPERIMENTAL
Intervention: High density electrical mapping during AX-CPT task
Number of subjects: 0
Study 11232987 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, ticlopidine, and further intravenous heparin infusion for 48 hours following primary coronary stenting (Group 1)
Number of subjects: 152
Study 11232987 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and ticlopidine without further heparin therapy following primary coronary stenting (Group 2)
Number of subjects: 152
Study 8626947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic low osmolar contrast media
Number of subjects: 211
Study 8626947 — intervention group
Group type: COMPARATOR
Intervention: Nonionic low osmolar contrast media
Number of subjects: 211